![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GPAM |
Gene summary for GPAM |
![]() |
Gene information | Species | Human | Gene symbol | GPAM | Gene ID | 57678 |
Gene name | glycerol-3-phosphate acyltransferase, mitochondrial | |
Gene Alias | GPAT | |
Cytomap | 10q25.2 | |
Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q86T70 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57678 | GPAM | NAFLD1 | Human | Liver | NAFLD | 5.36e-15 | 1.13e+00 | -0.04 |
57678 | GPAM | S41 | Human | Liver | Cirrhotic | 5.26e-04 | 6.47e-01 | -0.0343 |
57678 | GPAM | S43 | Human | Liver | Cirrhotic | 2.13e-06 | -4.77e-02 | -0.0187 |
57678 | GPAM | HCC1_Meng | Human | Liver | HCC | 1.60e-55 | 2.23e-02 | 0.0246 |
57678 | GPAM | HCC2_Meng | Human | Liver | HCC | 1.72e-06 | -1.61e-01 | 0.0107 |
57678 | GPAM | HCC1 | Human | Liver | HCC | 4.88e-33 | 5.45e+00 | 0.5336 |
57678 | GPAM | HCC2 | Human | Liver | HCC | 1.15e-06 | 2.23e+00 | 0.5341 |
57678 | GPAM | Pt14.a | Human | Liver | HCC | 1.60e-04 | 3.98e-01 | 0.0169 |
57678 | GPAM | Pt14.b | Human | Liver | HCC | 1.57e-03 | 2.42e-01 | 0.018 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00066316 | Liver | NAFLD | fatty acid metabolic process | 92/1882 | 390/18723 | 3.38e-15 | 3.29e-12 | 92 |
GO:00550883 | Liver | NAFLD | lipid homeostasis | 44/1882 | 167/18723 | 1.48e-09 | 2.54e-07 | 44 |
GO:00066413 | Liver | NAFLD | triglyceride metabolic process | 29/1882 | 100/18723 | 9.51e-08 | 7.62e-06 | 29 |
GO:00092596 | Liver | NAFLD | ribonucleotide metabolic process | 72/1882 | 385/18723 | 1.51e-07 | 1.09e-05 | 72 |
GO:00196936 | Liver | NAFLD | ribose phosphate metabolic process | 73/1882 | 396/18723 | 2.23e-07 | 1.53e-05 | 73 |
GO:00091177 | Liver | NAFLD | nucleotide metabolic process | 85/1882 | 489/18723 | 3.31e-07 | 2.18e-05 | 85 |
GO:00067537 | Liver | NAFLD | nucleoside phosphate metabolic process | 85/1882 | 497/18723 | 6.69e-07 | 3.83e-05 | 85 |
GO:00725217 | Liver | NAFLD | purine-containing compound metabolic process | 74/1882 | 416/18723 | 7.73e-07 | 4.27e-05 | 74 |
GO:00066392 | Liver | NAFLD | acylglycerol metabolic process | 32/1882 | 128/18723 | 8.82e-07 | 4.60e-05 | 32 |
GO:00066382 | Liver | NAFLD | neutral lipid metabolic process | 32/1882 | 129/18723 | 1.06e-06 | 5.35e-05 | 32 |
GO:00091507 | Liver | NAFLD | purine ribonucleotide metabolic process | 67/1882 | 368/18723 | 1.10e-06 | 5.44e-05 | 67 |
GO:00061637 | Liver | NAFLD | purine nucleotide metabolic process | 70/1882 | 396/18723 | 1.93e-06 | 8.23e-05 | 70 |
GO:00464863 | Liver | NAFLD | glycerolipid metabolic process | 66/1882 | 392/18723 | 1.94e-05 | 5.52e-04 | 66 |
GO:00067904 | Liver | NAFLD | sulfur compound metabolic process | 58/1882 | 339/18723 | 3.79e-05 | 9.38e-04 | 58 |
GO:00338653 | Liver | NAFLD | nucleoside bisphosphate metabolic process | 28/1882 | 128/18723 | 5.89e-05 | 1.30e-03 | 28 |
GO:00338753 | Liver | NAFLD | ribonucleoside bisphosphate metabolic process | 28/1882 | 128/18723 | 5.89e-05 | 1.30e-03 | 28 |
GO:00340323 | Liver | NAFLD | purine nucleoside bisphosphate metabolic process | 28/1882 | 128/18723 | 5.89e-05 | 1.30e-03 | 28 |
GO:00097437 | Liver | NAFLD | response to carbohydrate | 45/1882 | 253/18723 | 1.07e-04 | 2.11e-03 | 45 |
GO:00194322 | Liver | NAFLD | triglyceride biosynthetic process | 13/1882 | 42/18723 | 1.60e-04 | 2.94e-03 | 13 |
GO:00352643 | Liver | NAFLD | multicellular organism growth | 27/1882 | 132/18723 | 2.57e-04 | 4.19e-03 | 27 |
Page: 1 2 3 4 5 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa005615 | Liver | HCC | Glycerolipid metabolism | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
hsa0056112 | Liver | HCC | Glycerolipid metabolism | 41/4020 | 63/8465 | 3.59e-03 | 1.12e-02 | 6.22e-03 | 41 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GPAM | SNV | Missense_Mutation | c.2092N>A | p.Gly698Arg | p.G698R | Q9HCL2 | protein_coding | deleterious(0.01) | possibly_damaging(0.71) | TCGA-CD-5798-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
GPAM | SNV | Missense_Mutation | c.341N>C | p.Phe114Ser | p.F114S | Q9HCL2 | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
GPAM | SNV | Missense_Mutation | c.278N>G | p.Tyr93Cys | p.Y93C | Q9HCL2 | protein_coding | tolerated(0.17) | probably_damaging(0.98) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
GPAM | SNV | Missense_Mutation | c.953N>A | p.Arg318His | p.R318H | Q9HCL2 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-HF-7132-01 | Stomach | stomach adenocarcinoma | Male | Unknown | I/II | Chemotherapy | fluorouracil | SD | |
GPAM | SNV | Missense_Mutation | rs760613531 | c.1519N>A | p.Glu507Lys | p.E507K | Q9HCL2 | protein_coding | tolerated(0.41) | probably_damaging(0.972) | TCGA-HU-A4G8-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD |
GPAM | deletion | Frame_Shift_Del | c.1802delG | p.Gly601ValfsTer9 | p.G601Vfs*9 | Q9HCL2 | protein_coding | TCGA-CD-A4MG-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |||
GPAM | insertion | Frame_Shift_Ins | novel | c.1668_1669insT | p.Ile557TyrfsTer48 | p.I557Yfs*48 | Q9HCL2 | protein_coding | TCGA-HF-7132-01 | Stomach | stomach adenocarcinoma | Male | Unknown | I/II | Chemotherapy | fluorouracil | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |